Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

323

Participants

Timeline

Start Date

May 3, 2021

Primary Completion Date

July 31, 2024

Study Completion Date

July 31, 2026

Conditions

Onchocerciasis

Interventions

DRUG

Moxidectin

2mg tablets, encapsulated for blinding

DRUG

Ivermectin

3mg tablets, encapsulated for blinding

Trial Locations (1)

Centre de Recherche pour les Maladies Tropicales Negligees, Rethy

All Listed Sponsors

lead

Medicines Development for Global Health

OTHER

NCT03876262 - Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis | Biotech Hunter | Biotech Hunter